"Fluorodeoxyglucose F18" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The compound is given by intravenous injection to do POSITRON-EMISSION TOMOGRAPHY for the assessment of cerebral and myocardial glucose metabolism in various physiological or pathological states including stroke and myocardial ischemia. It is also employed for the detection of malignant tumors including those of the brain, liver, and thyroid gland. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1162)
| Descriptor ID |
D019788
|
| MeSH Number(s) |
D09.254.229.500
|
| Concept/Terms |
Fluorodeoxyglucose F18- Fluorodeoxyglucose F18
- F18, Fluorodeoxyglucose
- 18F-FDG
- Fluorodeoxyglucose F 18
- F 18, Fluorodeoxyglucose
- Fludeoxyglucose F 18
- F 18, Fludeoxyglucose
- Fluorine-18-fluorodeoxyglucose
- Fluorine 18 fluorodeoxyglucose
- 18F Fluorodeoxyglucose
- Fluorodeoxyglucose, 18F
- 18FDG
|
Below are MeSH descriptors whose meaning is more general than "Fluorodeoxyglucose F18".
Below are MeSH descriptors whose meaning is more specific than "Fluorodeoxyglucose F18".
This graph shows the total number of publications written about "Fluorodeoxyglucose F18" by people in this website by year, and whether "Fluorodeoxyglucose F18" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 1 | 1 | 2 |
| 2004 | 1 | 1 | 2 |
| 2005 | 1 | 1 | 2 |
| 2007 | 2 | 0 | 2 |
| 2008 | 0 | 2 | 2 |
| 2009 | 1 | 2 | 3 |
| 2010 | 0 | 2 | 2 |
| 2011 | 1 | 5 | 6 |
| 2012 | 0 | 2 | 2 |
| 2013 | 6 | 3 | 9 |
| 2014 | 3 | 10 | 13 |
| 2015 | 3 | 5 | 8 |
| 2016 | 3 | 2 | 5 |
| 2017 | 4 | 5 | 9 |
| 2018 | 3 | 1 | 4 |
| 2019 | 1 | 4 | 5 |
| 2020 | 4 | 4 | 8 |
| 2021 | 2 | 3 | 5 |
| 2022 | 2 | 3 | 5 |
| 2023 | 2 | 3 | 5 |
| 2024 | 3 | 3 | 6 |
| 2025 | 0 | 2 | 2 |
| 2026 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Fluorodeoxyglucose F18" by people in Profiles.
-
Phase 1 Trial of Withania somnifera Leaf Extract (RH324) in Advanced Non-Small Cell Lung Cancer Including [18F]FDG PET/CT as a Short-Term Metabolic Biomarker to Assess Efficacy: A Novel Model for Assessment of Complimentary Therapies in Early Phase Human Clinical Trials. Integr Cancer Ther. 2026 Jan-Dec; 25:15347354251410182.
-
EA1211: interim FDG-PET/CT for predicting response of HER2-positive breast cancer to neoadjuvant therapy (DIRECT trial). Future Oncol. 2025 Nov; 21(26):3377-3384.
-
Relationships between hypometabolism and both ?-amyloid and tau PET in corticobasal syndrome. Alzheimers Dement. 2025 03; 21(3):e70018.
-
A composite 18F-FDG PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant pertuzumab and trastuzumab in HER2-positive breast cancer (TBCRC026). Breast. 2025 Jun; 81:104432.
-
Phase 2 Trial Assessing Toxicity of Personalized Response-Based Radiation Treatment in Patients With Locally Advanced Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2024 Dec 01; 120(5):1332-1343.
-
18F-FDG PET/CT and radiolabeled leukocyte SPECT/CT imaging for the evaluation of cardiovascular infection in the multimodality context: ASNC Imaging Indications (ASNC I2) Series Expert Consensus Recommendations from ASNC, AATS, ACC, AHA, ASE, EANM, HRS, IDSA, SCCT, SNMMI, and STS. Heart Rhythm. 2024 05; 21(5):e1-e29.
-
Synthetic PET from CT improves diagnosis and prognosis for lung cancer: Proof of concept. Cell Rep Med. 2024 Mar 19; 5(3):101463.
-
18F-FDG PET/CT and Radiolabeled Leukocyte SPECT/CT Imaging for the Evaluation of Cardiovascular Infection in the Multimodality Context: ASNC Imaging Indications (ASNC I2) Series Expert Consensus Recommendations From ASNC, AATS, ACC, AHA, ASE, EANM, HRS, IDSA, SCCT, SNMMI, and STS. JACC Cardiovasc Imaging. 2024 Jun; 17(6):669-701.
-
18F-FDG PET/CT and radiolabeled leukocyte SPECT/CT imaging for the evaluation of cardiovascular infection in the multimodality context: ASNC Imaging Indications (ASNC I2) Series Expert Consensus Recommendations from ASNC, AATS, ACC, AHA, ASE, EANM, HRS, IDSA, SCCT, SNMMI, and STS. J Nucl Cardiol. 2024 04; 34:101786.
-
Heterogeneity and overlap in the continuum of linguistic profile of logopenic and semantic variants of primary progressive aphasia: a Profile Analysis based on Multidimensional Scaling study. Alzheimers Res Ther. 2024 03 07; 16(1):49.